EHA 2025: Real-World Insights on Belantamab Mafodotin in RRMM

In this MEDtalk, Dr. Fredrik Schjesvold, Founder and Leader of Oslo Myeloma Center, shares the findings from a real-world study on belantamab mafodotin monotherapy in relapsed/refractory multiple myeloma, presented at EHA 2025. The study demonstrated consistent efficacy in clinical trials and comparable ocular event rates between Europe and the US, despite differences in monitoring practices. Although the ocular events are manageable, and only very few patients stop treatment because of them, the study supports a more symptom-driven approach to ocular follow-up in clinical practice.